Precision Biosciences Inc (DTIL) · Insider trading
What Precision Biosciences's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$63,215
3 insiders, 6 trades
Sold, 12 months
$466,167
4 insiders, 100% under a plan
Net, 12 months
−$402,953
bought less sold
Latest filing
2026-09-30
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Amoroso MichaelDirector, President and CEO | – | $448,244 | 6 | 2026-02-18 | 243,392 |
| Kelly John AlexanderChief Financial Officer | $30,317 | $164,220 | 6 | 2026-02-18 | 125,883 |
| Smith J. JeffersonChief Research Officer | – | $110,049 | 4 | 2026-02-18 | 121,926 |
| Scimeca DarioGeneral Counsel and Secretary | – | $107,826 | 6 | 2026-02-18 | 56,457 |
| Germano Geno JDirector | $63,956 | – | 4 | 2026-09-25 | 47,492 |
| Buehler KevinDirector | $63,320 | – | 3 | 2025-06-25 | 28,137 |
| Brown MelindaDirector | $50,248 | – | 6 | 2026-09-25 | 45,481 |
| Frankel StanleyDirector | $32,109 | – | 3 | 2026-09-28 | 41,478 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Frankel StanleyDirector | Buy | 1,000 | 6.00 | $6,000 | 41,478 | Form 4 |
| 2026-09-25 | Germano Geno JDirector | Buy | 2,609 | 6.28 | $16,385 | 47,492 | Form 4 |
| 2026-09-25 | Brown MelindaDirector | Buy | 1,135 | 6.27 | $7,116 | 45,481 | Form 4 |
| 2026-02-18 | Smith J. JeffersonChief Research Officer | Saleplan | 4,925 | 3.84 | $18,912 | 121,926 | Form 4 |
| 2026-02-18 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 4,925 | 3.84 | $18,912 | 56,457 | Form 4 |
| 2026-02-18 | Kelly John AlexanderChief Financial Officer | Saleplan | 8,149 | 3.84 | $31,292 | 125,883 | Form 4 |
| 2026-02-18 | Amoroso MichaelDirector, President and CEO | Saleplan | 20,559 | 3.84 | $78,947 | 243,392 | Form 4 |
| 2026-01-22 | Amoroso MichaelDirector, President and CEO | Saleplan | 34,799 | 4.17 | $145,112 | 196,154 | Form 4 |
| 2026-01-21 | Smith J. JeffersonChief Research Officer | Saleplan | 10,200 | 4.03 | $41,106 | 110,184 | Form 4 |
| 2026-01-21 | Kelly John AlexanderChief Financial Officer | Saleplan | 15,213 | 4.03 | $61,308 | 106,448 | Form 4 |
| 2026-01-21 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 8,854 | 4.03 | $35,682 | 44,715 | Form 4 |
| 2025-12-16 | Frankel StanleyDirector | Buy | 2,700 | 4.70 | $12,690 | 19,478 | Form 4 |
| 2025-12-16 | Germano Geno JDirector | Buy | 3,000 | 4.72 | $14,160 | 23,883 | Form 4 |
| 2025-12-15 | Brown MelindaDirector | Buy | 1,381 | 4.97 | $6,864 | 23,346 | Form 4 |
| 2025-11-03 | Amoroso MichaelDirector, President and CEO | Saleplan | 3,409 | 6.49 | $22,124 | 115,575 | Form 4 |
| 2025-11-03 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 665 | 6.49 | $4,316 | 28,258 | Form 4 |
| 2025-11-03 | Kelly John AlexanderChief Financial Officer | Saleplan | 1,303 | 6.49 | $8,456 | 77,298 | Form 4 |
| 2025-09-26 | Frankel StanleyDirector | Buy | 2,700 | 4.97 | $13,419 | 16,778 | Form 4 |
| 2025-09-22 | Brown MelindaDirector | Buy | 1,400 | 4.89 | $6,846 | 21,965 | Form 4 |
| 2025-07-03 | Kelly John AlexanderChief Financial Officer | Saleplan | 14,827 | 4.26 | $63,163 | 73,485 | Form 4 |
| 2025-06-25 | Buehler KevinDirector | Buy | 5,076 | 4.16 | $21,116 | 28,137 | Form 4 |
| 2025-06-25 | Brown MelindaDirector | Buy | 1,682 | 4.14 | $6,963 | 20,565 | Form 4 |
| 2025-03-26 | Buehler KevinDirector | Buy | 4,523 | 4.67 | $21,122 | 13,235 | Form 4 |
| 2025-03-26 | Brown MelindaDirector | Buy | 1,839 | 4.75 | $8,735 | 9,057 | Form 4 |
| 2025-03-25 | Germano Geno JDirector | Buy | 3,250 | 5.30 | $17,225 | 11,057 | Form 4 |
| 2025-03-24 | Amoroso MichaelDirector, President and CEO | Saleplan | 964 | 5.56 | $5,360 | 109,540 | Form 4 |
| 2025-03-04 | Smith J. JeffersonChief Research Officer | Saleplan | 154 | 4.91 | $756 | 87,805 | Form 4 |
| 2025-03-04 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 272 | 4.91 | $1,336 | 25,000 | Form 4 |
| 2025-01-22 | Smith J. JeffersonChief Research Officer | Saleplan | 10,287 | 4.79 | $49,275 | 87,440 | Form 4 |
| 2025-01-22 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 8,928 | 4.79 | $42,765 | 24,353 | Form 4 |
| 2025-01-21 | Amoroso MichaelDirector, President and CEO | Saleplan | 36,838 | 4.67 | $172,033 | 107,087 | Form 4 |
| 2024-12-30 | Germano Geno JDirector | Buy | 3,605 | 4.49 | $16,186 | 7,807 | Form 4 |
| 2024-12-27 | Kelly John AlexanderChief Financial Officer | Buy | 2,113 | 4.75 | $10,037 | 40,186 | Form 4 |
| 2024-12-27 | Buehler KevinDirector | Buy | 4,320 | 4.88 | $21,082 | 8,712 | Form 4 |
| 2024-12-26 | Brown MelindaDirector | Buy | 3,016 | 4.55 | $13,723 | 7,218 | Form 4 |
| 2024-11-21 | Kelly John AlexanderChief Financial Officer | Buy | 3,000 | 6.76 | $20,280 | 38,073 | Form 4 |
| 2024-11-04 | Amoroso MichaelDirector, President and CEO | Sale | 3,012 | 8.19 | $24,668 | 28,537 | Form 4 |
| 2024-11-04 | Scimeca DarioGeneral Counsel and Secretary | Saleplan | 588 | 8.19 | $4,816 | 7,969 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
40 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Germano Geno JDirector | Option exercise M | +21,000 | – | 44,883 | Form 4 |
| 2026-05-20 | Pire Shari LisaDirector | Option exercise M | +21,000 | – | 35,028 | Form 4 |
| 2026-05-20 | Brown MelindaDirector | Option exercise M | +21,000 | – | 44,346 | Form 4 |
| 2026-05-20 | Frankel StanleyDirector | Option exercise M | +21,000 | – | 40,478 | Form 4 |
| 2026-05-20 | Buehler KevinDirector | Option exercise M | +21,000 | – | 49,137 | Form 4 |
| 2026-02-17 | Smith J. JeffersonChief Research Officer | Option exercise M | +16,667 | – | 126,851 | Form 4 |
| 2026-02-17 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +16,667 | – | 61,382 | Form 4 |
| 2026-02-17 | Kelly John AlexanderChief Financial Officer | Option exercise M | +27,584 | – | 134,032 | Form 4 |
| 2026-02-17 | Amoroso MichaelDirector, President and CEO | Option exercise M | +67,797 | – | 263,951 | Form 4 |
| 2026-01-21 | Smith J. JeffersonChief Research Officer | Option exercise M | +16,219 | – | 120,384 | Form 4 |
| 2026-01-20 | Smith J. JeffersonChief Research Officer | Option exercise M | +2,500 | – | 93,718 | Form 4 |
| 2026-01-20 | Smith J. JeffersonChief Research Officer | Option exercise M | +10,447 | – | 104,165 | Form 4 |
| 2026-01-20 | Kelly John AlexanderChief Financial Officer | Option exercise M | +3,888 | – | 81,186 | Form 4 |
| 2026-01-20 | Kelly John AlexanderChief Financial Officer | Option exercise M | +13,900 | – | 95,086 | Form 4 |
| 2026-01-20 | Kelly John AlexanderChief Financial Officer | Option exercise M | +26,575 | – | 121,661 | Form 4 |
| 2026-01-20 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +1,978 | – | 30,236 | Form 4 |
| 2026-01-20 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +8,425 | – | 38,661 | Form 4 |
| 2026-01-20 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +14,908 | – | 53,569 | Form 4 |
| 2026-01-20 | Amoroso MichaelDirector, President and CEO | Option exercise M | +8,888 | – | 124,463 | Form 4 |
| 2026-01-20 | Amoroso MichaelDirector, President and CEO | Option exercise M | +37,069 | – | 161,532 | Form 4 |
| 2026-01-20 | Amoroso MichaelDirector, President and CEO | Option exercise M | +69,421 | – | 230,953 | Form 4 |
| 2025-11-02 | Amoroso MichaelDirector, President and CEO | Option exercise M | +9,444 | – | 118,984 | Form 4 |
| 2025-11-02 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +1,835 | – | 28,923 | Form 4 |
| 2025-11-02 | Kelly John AlexanderChief Financial Officer | Option exercise M | +3,605 | – | 78,601 | Form 4 |
| 2025-05-27 | Brown MelindaDirector | Option exercise M | +9,826 | – | 18,883 | Form 4 |
| 2025-05-27 | Buehler KevinDirector | Option exercise M | +9,826 | – | 23,061 | Form 4 |
| 2025-05-27 | Frankel StanleyDirector | Option exercise M | +9,826 | – | 14,078 | Form 4 |
| 2025-05-27 | Pire Shari LisaDirector | Option exercise M | +9,826 | – | 14,028 | Form 4 |
| 2025-05-27 | Germano Geno JDirector | Option exercise M | +9,826 | – | 20,883 | Form 4 |
| 2025-03-21 | Amoroso MichaelDirector, President and CEO | Option exercise M | +3,417 | – | 110,504 | Form 4 |
| 2025-03-03 | Kelly John AlexanderChief Financial Officer | Option exercise M | +1,702 | – | 86,256 | Form 4 |
| 2025-03-03 | Smith J. JeffersonChief Research Officer | Option exercise M | +519 | – | 87,959 | Form 4 |
| 2025-03-03 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +919 | – | 25,272 | Form 4 |
| 2025-01-20 | Smith J. JeffersonChief Research Officer | Option exercise M | +29,168 | – | 97,727 | Form 4 |
| 2025-01-20 | Kelly John AlexanderChief Financial Officer | Option exercise M | +44,368 | – | 84,554 | Form 4 |
| 2025-01-20 | Amoroso MichaelDirector, President and CEO | Option exercise M | +115,388 | – | 143,925 | Form 4 |
| 2025-01-20 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +25,312 | – | 33,281 | Form 4 |
| 2024-11-02 | Amoroso MichaelDirector, President and CEO | Option exercise M | +9,443 | – | 31,549 | Form 4 |
| 2024-11-02 | Scimeca DarioGeneral Counsel and Secretary | Option exercise M | +1,836 | – | 8,557 | Form 4 |
| 2024-11-02 | Kelly John AlexanderChief Financial Officer | Option exercise M | +3,605 | – | 35,073 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.